How to Make an Ebola Vaccine: 5 (Simplified) Steps

We’re only on step three.

Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials with the ebola vaccine called Chimp Adenovirus type 3 (ChAd3), holds up the vaccine before the first healthy UK volunteer receives their ebola vaccine.
National Journal
Oct. 29, 2014, 1 a.m.

Jo­nas Salk, in­vent­or of the polio vac­cine, was born 100 years ago this week, and the con­tri­bu­tions he made to sci­ence still save count­less lives. That’s be­cause the sci­entif­ic dogma be­hind his vac­cine still holds true: If you ex­pose a body to de­ac­tiv­ated, non­con­ta­gious ver­sion of a vir­us, when a live bug comes along, that body will be ready.

The same prin­ciple would ap­ply to an Ebola vac­cine. That is, if one was avail­able for the hu­man body. Ebola vac­cines ex­ist, but un­til now, they have only been tested in mon­keys.

Hu­man clin­ic­al tri­als for an Ebola vac­cine began only this year. The World Health Or­gan­iz­a­tion re­ports the data from these first tests will be avail­able in Decem­ber.

“We need to speed up that time point,” says Clive Gray, a pro­fess­or of im­mun­o­logy at the Uni­versity of Cape Town in South Africa. By Decem­ber, the ef­forts may be too little, too late. And res­ults from the first phase of tri­als don’t mean wide-scale pro­duc­tion. They mean more clin­ic­al tri­als. The time clock is grim and run­ning thin: The most pess­im­ist­ic scen­ari­os pre­dict as many as 1.4 mil­lion cases of the dis­ease by Janu­ary.

It’s not the sci­ence that has held an Ebola vac­cine back. In 2005, re­search­ers re­por­ted a vac­cine that was 100 per­cent ef­fect­ive in pro­tect­ing mon­keys from the ill­ness. That should have pro­moted a hu­man tri­al. But it didn’t.

“The cur­rent Ebola out­break is the same vir­al strain — the Zaire Ebola vir­us strain — as the very first out­break.”

Why? Simply and sadly, it was bad busi­ness for drug man­u­fac­tur­ers. Past out­breaks have been small and con­fined to poor coun­tries with fal­ter­ing pub­lic-health sys­tems. Now, with in­ter­na­tion­al at­ten­tion fo­cused on Ebola, an Ebola vac­cine will be­come a real­ity. WHO re­ports that clin­ic­al tri­als are un­der­way in three coun­tries and will soon com­mence in four oth­ers.

But the crux of the Ebola-vac­cine prob­lem is this: It takes time to take a vac­cine that’s ef­fect­ive in mon­keys and en­sure its safety and ef­fic­acy in hu­mans.  “As we ac­cel­er­ate in a mat­ter of weeks a pro­cess that typ­ic­ally takes years, we are en­sur­ing that safety re­mains the top pri­or­ity, with pro­duc­tion speed and ca­pa­city a close second,” Mar­ie-Paule Kieny, WHO as­sist­ant dir­ect­or-gen­er­al, said in a press re­lease.

So what does it take to bring a vac­cine from the lab to the field where it is des­per­ately needed? I asked Dr. Gray to lay out how it would work. To sim­pli­fy, it takes five steps. And we’re only on Step 3.

Step 1: Identi­fy the Tar­get

The first step in cre­at­ing a vac­cine is to study the struc­ture of the vir­us. Know­ing the struc­ture al­lows sci­ent­ists to mim­ic its struc­ture in a ser­um. Again, that’s the key to an ef­fect­ive vac­cine: to in­ject in­to some­body a sub­stance that looks like the vir­us, but is not the vir­us.

This pro­cess is a lot harder for some vir­uses than oth­ers. HIV and the flu, for in­stance, are con­stantly mutat­ing, cre­at­ing new forms that can fool the im­mune sys­tem. That’s why a new flu strain crops up every year. HIV is even more elu­sive — it can mutate and evade an im­mune re­sponse with­in one per­son’s body.

Thank­fully, Ebola isn’t like the flu or HIV. “The cur­rent Ebola out­break is the same vir­al strain — the Zaire Ebola vir­us strain — as the very first out­break,” Gray says. “And it hasn’t changed. Each per­son who be­comes in­fec­ted, gets in­fec­ted with the same vir­us.” That means one vac­cine can pro­tect all people from Ebola, without the need for yearly up­dates.

Step 2: Mim­ic the Tar­get

All the im­mune sys­tem needs to identi­fy a vir­us is the vir­us’s out­er pro­tein coat. The out­er pro­tein coat is the vir­us’s call­ing card. That’s what sci­ent­ists have re­cre­ated in the Ebola vac­cines now in tri­al. “They are tak­ing the ge­net­ic ma­ter­i­al from Ebola that codes for the pro­tein coat and they in­sert that ge­net­ic ma­ter­i­al in­to the skel­et­on of an­oth­er vir­us,” Gray says.

That skel­et­on vir­us won’t get a per­son sick, but will, in a sense, tell the im­mune sys­tem about the Ebola vir­us. The body will then start pro­du­cing the an­ti­bod­ies ne­ces­sary to con­tain Ebola.

Step 3: Test in An­im­als

The an­im­al tests en­sure that the vac­cine pro­vokes the in­ten­ded im­mune re­sponse against the Ebola vir­us. “The an­im­al test­ing has been done on these ex­ist­ing vac­cines,” Gray says. “That’s where the field is at now.”

Up un­til this point, The New York Times ex­plains, “the re­search may have cost a few mil­lion dol­lars, but tests in hu­mans and scal­ing up pro­duc­tion can cost hun­dreds of mil­lions, and bring­ing a new vac­cine all the way to mar­ket typ­ic­ally costs $1 bil­lion to $1.5 bil­lion.” And that’s why we’ve stalled at Step 3.

Step 4: Test in Hu­mans

That an­im­al-tested vac­cine would not give any hu­man Ebola, but that doesn’t mean it’s safe for hu­mans. Early-stage vac­cines can have dan­ger­ous side ef­fects.

In the very first clin­ic­al tri­als, re­search­ers “are put­ting these vac­cines in­to people to make sure they are safe, and also to see if the im­mune re­sponse in the people looks very sim­il­ar to the im­mune re­sponse in the mon­keys in the an­im­al stud­ies,” Gray says. Once it is de­term­ined to be safe and ef­fect­ive, the cor­rect dosage needs to be as­sessed. “If you give too much, maybe it would make the per­son feel sick, and if you give too little, it won’t be ef­fect­ive,” he says.

Re­search­ers will also con­sider the mode of in­jec­tion — should it be in­jec­ted in­to the muscle or just un­der the skin?

These clin­ic­al tri­als need to be con­duc­ted care­fully, and can of­ten take years to en­sure a vac­cine that is safe for mass con­sump­tion. “You can­not give people something that is un­safe,” Gray says.

Step 5: Pro­duce and Dis­perse

What does this step in­volve? “Fund­ing, simple as that,” Gray says. “If you give enough money, if you give enough dol­lars, it can be scaled up quickly.” Glaxo­S­mithK­line, the phar­ma­ceut­ic­al mega-gi­ant, has es­tim­ated it could pro­duce 1 mil­lion doses of a vac­cine a month by 2016. Two years might be light­en­ing fast when it comes to drug ap­provals, but when look­ing at the tra­ject­ory of the cur­rent Ebola out­break, two years may be an etern­ity.

What We're Following See More »
8 SCHOOLS INCLUDING YALE, STANFORD, GEORGETOWN
Dept. of Education Opens Probe into College Admissions Scandal
9 hours ago
THE LATEST
HAD BEEN SCHEDULED FOR WEDNESDAY
House Intel Postpones Testimony by Felix Sater
12 hours ago
THE LATEST
PASSED 420-0 IN THE HOUSE
McConnell Blocks Vote on Making Mueller Report Public
12 hours ago
THE LATEST
CITES "VERY CONCERNING DISCREPANCIES"
Nadler Intends to Call Barr to Testify
20 hours ago
THE LATEST
PICTURE IS CLOUDIER ON OBSTRUCTION
Mueller: No Evidence of Collusion
1 days ago
THE LATEST

"The investigation led by Robert S. Mueller III found that neither President Trump nor any of his aides conspired or coordinated with the Russian government’s 2016 election interference, according to a summary of the special counsel’s findings made public on Sunday by Attorney General William P. Barr. The summary also said that the special counsel’s team lacked sufficient evidence to establish that President Trump illegally obstructed justice, but added that Mr. Mueller’s team stopped short of exonerating Mr. Trump." Read Barr's summary here.

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login